China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance

Reuters

Nov 18, 2025

China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance

China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China (PRC). The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584318519"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584318519\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584318519?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584318519","market":"fut","top_or_hot":-1,"title":"China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China (PRC). The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China (PRC). The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1570","symbol_name":"华润系","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL4wr5mS:1","article_id":"2584318519","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584318519","pubTimestamp":1763465166,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China . The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1570":"华润系","03320":"华润医药","BK1191":"制药"},"translate_title":"华润医药集团完成人民币11亿元公司债券发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":0.9},"content_text":"China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance\n    \n\n        China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China (PRC). The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}